Pathology: la/mBC - HER2 positive - 1st Line (L1); la/mBC - HER2 positive - 2nd Line (L2);
| la/mBC - HER2 positive - 1st Line (L1) | la/mBC - HER2 positive - 2nd Line (L2) | |||||||||
| PERTAIN, 2018 | CLEOPATRA, 2012 | PUFFIN, 2020 | SYSUCC-002, 2022 | ExteNET, 2016 | NALA (brain metastases), 2020 | NALA, 2020 | HER2CLIMB (patients with brain metastases), 2020 | HER2CLIMB, 2020 | ||
| neratinib plus capecitabine | 2 | T1 | T1 | |||||||
| tucatinib plus trastuzumab plus capecitabine | 2 | T1 | T1 | |||||||
| pertuzumab plus trastuzumab plus docetaxel | 2 | T1 | T1 | |||||||
| trastuzumab plus endocrine therapy | 1 | T1 | ||||||||
| pertuzumab plus trastuzumab | 1 | T1 | ||||||||
| neratinib | 1 | T1 | ||||||||
| trastuzumab plus chemotherapy | 0 | T0 | ||||||||
| lapatinib plus capecitabine | 0 | T0 | T0 | |||||||
| trastuzumab plus capecitabine | 0 | T0 | T0 | |||||||
| trastuzumab | 0 | T0 | ||||||||
| trastuzumab plus docetaxel | 0 | T0 | T0 | |||||||
| placebo | 0 | T0 | ||||||||